Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation

[1]  Jeff S. Jasper,et al.  27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology , 2013, Science.

[2]  V. Giguère,et al.  Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond , 2012, Nature Reviews Cancer.

[3]  S. Tavazoie,et al.  Convergent Multi-miRNA Targeting of ApoE Drives LRP1/LRP8-Dependent Melanoma Metastasis and Angiogenesis , 2012, Cell.

[4]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[5]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[6]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[7]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[8]  S. Nelson,et al.  Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.

[9]  S. Tavazoie,et al.  A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells , 2011, Nature.

[10]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[11]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[12]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[13]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[14]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[15]  I. Fidler,et al.  AACR centennial series: the biology of cancer metastasis: historical perspective. , 2010, Cancer research.

[16]  D. Heimbrook,et al.  RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. , 2010, Cancer research.

[17]  A. Bookout,et al.  Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. , 2010, Molecular endocrinology.

[18]  John A Thompson,et al.  Treatment of metastatic melanoma: an overview. , 2009, Oncology.

[19]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[20]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[21]  Miriam K. Konkel,et al.  Genome analysis of the platypus reveals unique signatures of evolution , 2008, Nature.

[22]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[23]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[24]  M. Jaye,et al.  Synthetic LXR agonists increase LDL in CETP species Published, JLR Papers in Press, July 16, 2005. DOI 10.1194/jlr.M500116-JLR200 , 2005, Journal of Lipid Research.

[25]  Mingui Fu,et al.  A Nuclear Receptor Atlas: 3T3-L1 adipogenesis. , 2005, Molecular endocrinology.

[26]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[27]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[28]  R. Blasberg,et al.  A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[30]  D. Mangelsdorf,et al.  Regulated Expression of the Apolipoprotein E/C-I/C-IV/C-II Gene Cluster in Murine and Human Macrophages , 2002, The Journal of Biological Chemistry.

[31]  Timothy M Willson,et al.  Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. , 2002, Journal of medicinal chemistry.

[32]  D. Mangelsdorf,et al.  LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[34]  D. Mangelsdorf,et al.  An oxysterol signalling pathway mediated by the nuclear receptor LXRα , 1996, Nature.

[35]  K. Umesono,et al.  LXR, a nuclear receptor that defines a distinct retinoid response pathway. , 1995, Genes & development.

[36]  R. Hiipakka,et al.  Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Pfahl,et al.  A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily , 1994, Molecular and cellular biology.

[38]  I. Fidler,et al.  Use of young nude mice for selection of subpopulations of cells with increased metastatic potential from nonsyngeneic neoplasms. , 1982, Journal of the National Cancer Institute.

[39]  A. McMichael,et al.  Solar Ultraviolet Radiation: Global burden of disease from solar ultraviolet radiation , 2006 .

[40]  A. Hauschild,et al.  The Oncologist® Academia–Pharma Intersect: Melanoma , 2022 .